David Domzalski - Sep 2, 2021 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role
President and CEO, Director
Signature
/s/ Mutya Harsch, attorney-in-fact for David Domzalski
Stock symbol
VYNE
Transactions as of
Sep 2, 2021
Transactions value $
$0
Form type
4
Date filed
9/3/2021, 05:33 PM
Previous filing
Jul 2, 2021
Next filing
Oct 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VYNE Common Stock Award $0 +320K +70.31% $0.00 776K Sep 2, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VYNE Stock Options Award $0 +320K $0.00 320K Sep 2, 2021 Common Stock 320K $1.68 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock units, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. 100% of the awards will vest on September 30, 2023, subject to the Reporting Person's continued service through the vesting date.
F2 50% of the shares subject to the stock option award will vest on September 30, 2022, and the remaining 50% of the shares will vest thereafter in equal, quarterly installments, subject to the Reporting Person's continued service through the vesting date.